Semax

Semax is a synthetic ACTH(4-10) fragment approved in Russia for stroke and cerebrovascular indications. Rodent studies show it upregulates the BDNF/trkB system and raises serotonin turnover. It is not FDA-approved, and the human evidence is uncontrolled and unreplicated outside Russia.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH), extended with a C-terminal Pro-Gly-Pro sequence to improve metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences beginning in the 1980s and officially registered with the Russian Ministry of Health in 2011 as a prescription drug under the INN 'semax.' Russia and Ukraine currently approve it for acute ischemic stroke, chronic cerebrovascular insufficiency, cognitive and memory disorders, peptic ulcer disease, and optic nerve atrophy — a breadth of indication reflecting decades of state-funded research largely unavailable in Western scientific literature.

Three primary variants exist. Standard Semax (the base heptapeptide) has a plasma half-life of approximately 2–3 minutes due to rapid aminopeptidase cleavage; it relies on quick CNS uptake via intranasal delivery to produce downstream effects that persist for hours despite the peptide itself being cleared within minutes. N-Acetyl Semax adds an acetyl group to the N-terminus, which is intended to slow enzymatic degradation and extend the effective half-life. N-Acetyl Semax Amidate (NASemax-A) additionally replaces the C-terminal carboxyl group with an amide. Both variants are widely described in the research-peptide market as more potent than the base peptide, but we have not found published head-to-head potency or pharmacokinetic comparisons in PubMed-indexed literature, so no multiplier is quoted here. Neither modified variant is the registered pharmaceutical form in Russia.

Western regulatory status is research-only: Semax is not FDA-approved, not a scheduled substance under the US Controlled Substances Act, and not subject to WADA anti-doping restrictions. This has made it accessible through research peptide suppliers, though product quality varies widely without compounding pharmacy oversight. The Russian pharmaceutical-grade product (Semax nasal solution 0.1% and 1%) remains the reference standard against which preclinical and clinical research was conducted.

The cognitive profile of Semax is frequently described as 'clean' — focused attention, improved working memory, and faster mental processing without the jitteriness, cardiovascular stimulation, or post-dose crash associated with amphetamines, racetams, or caffeine. This is consistent with its predominantly neurotrophic and monoaminergic mechanism rather than direct catecholamine release. Users report subjective effects within 15–30 minutes of intranasal dosing that persist 4–8 hours, with cycle lengths of 10–14 days being standard in Russian clinical practice.

Semax's cognitive and neuroprotective effects emerge from convergent actions on monoaminergic neurotransmission and neurotrophic factor expression. At the neurotransmitter level, Eremin et al. (Neurochem Res, 2005) found that Semax 0.15 mg/kg intraperitoneally in rodents raised tissue 5-hydroxyindoleacetic acid (5-HIAA, the primary serotonin metabolite) in the striatum by 25% at 2 hours, and raised extracellular striatal 5-HIAA progressively to about 180% of baseline over 1 to 4 hours. Notably, Semax alone did not alter dopamine or its metabolites in that study; it did strongly amplify the dopamine release and locomotor response to amphetamine given afterwards. So the dopaminergic story is one of modulation of an existing signal, not direct release.

The BDNF axis is Semax's most distinctive mechanism. BDNF (brain-derived neurotrophic factor) supports hippocampal neurogenesis, dendritic spine density, and long-term potentiation — the cellular substrate of learning and memory. Dolotov et al. (Brain Res, 2006) gave rats a single 50 μg/kg dose of Semax and measured, in hippocampus, a maximal 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, and 3-fold and 2-fold increases in exon III BDNF and trkB mRNA respectively; treated animals also showed more conditioned avoidance reactions. TrkB, the high-affinity BDNF receptor, is therefore both upregulated and more activated, amplifying the sensitivity of target neurons to endogenous BDNF.

In ischemic contexts, Semax alters expression of immune-response and neurotrophic genes in rat brain (Medvedeva et al., Mol Genet Genomics 2017), and animal work has reported neuroprotection in models of dopaminergic lesion (Levitskaya et al., Neurosci Behav Physiol 2004). The intranasal route is the clinically used one. In a direct route comparison (Manchenko et al., 2010), intranasal Semax was more potent than intraperitoneal dosing at improving learning in rats, though it failed to produce the analgesic effect that intraperitoneal dosing did — suggesting the two routes engage partly different mechanisms rather than intranasal simply being a better version of the same delivery.

The clinical evidence base for Semax is predominantly Russian-language and concentrated in stroke and cerebrovascular disease. The most substantial published study is Gusev et al. (Zh Nevrol Psikhiatr, 2018; PMID 29798983), which followed 110 patients after ischemic stroke. Patients were split into early (about 89 days post-stroke) and late (about 214 days) rehabilitation groups, each subdivided into those who did and did not receive semax at 6,000 mcg/day in two 10-day courses. Semax raised plasma BDNF, which stayed elevated through the study, and accelerated and improved final Barthel Index recovery; effects on motor performance were smaller. This was not a placebo-controlled trial and the comparison was semax versus no semax within a rehabilitation program, so it does not support claims about treatment within the first hours of stroke onset.

At the molecular level, Dolotov et al. (Brain Res, 2006; PMID 16996037) quantified Semax's neurotrophic action in rats: a single 50 μg/kg dose produced a maximal 1.4-fold increase in hippocampal BDNF protein, a 1.6-fold increase in trkB phosphorylation, and 3-fold and 2-fold increases in BDNF exon III and trkB mRNA. Eremin et al. (Neurochem Res, 2005; PMID 16362768) characterized monoaminergic effects, finding extracellular striatal 5-HIAA rising to about 180% of baseline over 1 to 4 hours, with no change in dopamine unless amphetamine was co-administered.

Route of administration was compared directly by Manchenko et al. (2010; PMID 21268834): intranasal Semax outperformed intraperitoneal dosing on learning in rats, but only intraperitoneal dosing produced analgesia, which the authors read as evidence that the two effects run through different mechanisms and brain structures.

The primary limitation of the Semax evidence base is that nearly all clinical trials were conducted in Russia under regulatory frameworks that differ from FDA or EMA standards, with variable blinding and outcome reporting quality by contemporary standards. Independent replication in Western academic settings is essentially absent. We have not been able to verify published, PubMed-indexed clinical trials of Semax for mild cognitive impairment in a non-stroke population, or head-to-head comparisons of the acetylated and amidated variants, so no figures for those are given here.[1][2][3][4][5][6]

Peptides commonly paired with Semax for synergistic effects.